Overview of Dr. Lamanna
Dr. Nicole Lamanna is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 20 years. Dr. Lamanna accepts several types of health insurance, listed below. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 378 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 90 publications and over 500 citings.
Office
622 W 168th St
New York, NY 10032
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- NYU Grossman School of MedicineResidency, Internal Medicine, 1997 - 2000
- Albert Einstein College of MedicineClass of 1997
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 1998 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014
- Top Doctors: New York Metro Area Castle Connolly, 2014
Clinical Trials
- Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Start of enrollment: 1996 Mar 01
- Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2005 May 01
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 46 citationsALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.Peter Hillmen, Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, S. M. O'Brien
Future Oncology. 2020-03-24 - 1292 citationsIdelalisib and rituximab in relapsed chronic lymphocytic leukemia.Richard R. Furman, Jeff P. Sharman, Steven Coutre, Bruce D. Cheson, John M. Pagel
The New England Journal of Medicine. 2014-03-12 - 229 citationsPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel
Lancet. 2021-03-06
Journal Articles
- Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic LeukemiaVincent Miller, Tariq Mughal, Nicole Lamanna, Andrew Zelenetz, Mark L Heaney, Mark G Frattini, Nature
- Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United StatesArun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
- The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLLMatthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Nicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesNicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesNicole Lamanna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- “Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”April 18th, 2023
- Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
- Clinical Challenges: Optimizing CLL TreatmentDecember 17th, 2021
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPOGreat West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: